Chris is an Entrepreneur-in-Residence on the Frazier Life Sciences team and an experienced business leader in therapeutic development and commercialization.
Chris joined Frazier in May 2017 and is currently the Chief Executive Officer of Mirum Pharmaceuticals, where he serves on the board of directors. He also serves on the board of Alpine Immune Sciences.
Chris previously served as Chief Financial Officer and Head of Corporate Development at Frazier portfolio company Tobira Therapeutics, a leading developer of therapeutics for non-alcoholic steatohepatitis. While at Tobira, Chris led the company's efforts to become a public company, expand its pipeline through partnership and in-licensing, and sell the company to Allergan for total consideration of up to $1.7 billion. Prior to Tobira, Chris held business leadership roles at Jennerex Biotherapeutics, Onyx Pharmaceuticals and Abgenix.
Chris holds a B.S.B.A. from Washington University in St. Louis and an M.B.A. from the Stanford Graduate School of Business.
Washington University (B.S.B.A)
Stanford University (M.B.A.)